Hexarelin is a synthetic growth hormone secretagogue peptide (GHS) and potent GHSR-1a agonist, developed to stimulate endogenous growth hormone (GH) release. It belongs to the ghrelin mimetic family and is composed of six amino acids (a hexapeptide), offering enhanced metabolic stability and stronger GH-releasing effects compared to earlier analogs like GHRP-6.
Hexarelin is widely studied for its applications in endocrinology, muscle wasting, cardiac repair, and anti-aging therapies, due to its ability to naturally elevate GH and insulin-like growth factor 1 (IGF-1) levels without directly introducing external hormones.
Hexarelin binds to the growth hormone secretagogue receptor (GHSR-1a) on the pituitary and hypothalamus, mimicking the action of ghrelin—the body’s natural hunger and GH-releasing hormone.
Key physiological actions:
Stimulates pulsatile GH release
Increases circulating IGF-1 levels
Promotes anabolic effects (muscle growth, recovery)
Supports fat metabolism and cell regeneration
May exhibit cardioprotective and anti-apoptotic effects
Unlike some other GHS peptides, Hexarelin does not significantly increase cortisol or prolactin, offering a cleaner endocrine profile.
Promotes lean body mass development
Enhances muscle repair and regeneration
Studied in sarcopenia, cachexia, and post-surgical recovery
Preclinical studies show improved cardiac function after myocardial injury
Reduces cardiac fibrosis and enhances left ventricular ejection fraction
Potential use in heart failure and cardiac aging models
Increases lipolysis and improves insulin sensitivity
Supports anti-aging therapies through GH/IGF-1 axis stimulation
May help maintain bone density and joint health
Purity ≥ 99%
Produced via solid-phase peptide synthesis (SPPS)
GMP-like standards, low endotoxin and solvent residues
Flexible supply: R&D to commercial scale